{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:46:17Z","timestamp":1753875977905,"version":"3.41.2"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23KD111995-01A1"],"award-info":[{"award-number":["K23KD111995-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We compared real-world healthcare resource utilization (HRU), Crohn\u2019s disease (CD)-related complications, and time to systemic corticosteroid discontinuation between patients with CD treated with adalimumab versus vedolizumab as initial biologic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Biologic-na\u00efve adults with CD and \u22652 claims between 05\/20\/2014 and 09\/30\/2019 for adalimumab or vedolizumab were identified in the IBM MarketScan research database. Patient characteristics were assessed during the 6-month baseline period before biologic initiation (index date). Adalimumab- and vedolizumab-treated patients were propensity score-matched 1:1 on demographics, disease characteristics, and comorbidities with \u226510% prevalence that differed significantly between groups. Categorical, continuous, and time-to-event outcomes between groups during the 12-month follow-up on\/after index were compared with chi-square tests, Wilcoxon rank-sum tests, and Kaplan\u2013Meier analyses, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Adalimumab- and vedolizumab-treated patients were matched (n = 461 per group) and baseline characteristics balanced. Significantly fewer adalimumab- versus vedolizumab-treated patients had a CD-related emergency room visit (12-month proportion: 14.5% vs 21.0%; log-rank P &amp;lt; 0.01) or inpatient admission (14.9% vs 20.2%; log-rank P &amp;lt; 0.05). Rates of CD-related surgeries were similar (9.3% vs 11.5%; log-rank P = 0.282). Among patients without internal\/perianal abscess or fistula or intestinal stricture at baseline (NADA = 360, NVDZ = 364), numerically but not significantly fewer adalimumab- versus vedolizumab-treated patients had CD-related complications at 12 months (18.3% vs 22.3%; P = 0.171). Among patients with corticosteroid use at index (NADA = 143, NVDZ = 139), significantly more adalimumab- versus vedolizumab-treated patients discontinued corticosteroids (12-month proportion: 90.2% vs 76.3%; log-rank P &amp;lt; 0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with CD treated with adalimumab as their first biologic experienced significantly lower CD-related HRU and were more likely to discontinue corticosteroids compared to vedolizumab-treated patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otac029","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T16:40:03Z","timestamp":1659631203000},"source":"Crossref","is-referenced-by-count":1,"title":["Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn\u2019s Disease: A Retrospective Claims Database Analysis"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-3758","authenticated-orcid":false,"given":"Ryan C","family":"Ungaro","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Griffith","sequence":"additional","affiliation":[{"name":"AbbVie, Inc. , North Chicago, Illinois , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Garcia-Horton","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aolin","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond K","family":"Cross","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, University of Maryland School of Medicine , Baltimore, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"issue":"7","key":"2022111812330847700_CIT0001","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","article-title":"Crohn disease: epidemiology, diagnosis, and management.","volume":"92","author":"Feuerstein","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2022111812330847700_CIT0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2022111812330847700_CIT0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40258-018-0432-4","article-title":"Trends and factors associated with hospitalization costs for inflammatory bowel disease in the United States","volume":"17","author":"Xu","year":"2019","journal-title":"Appl Health Econ Health Policy."},{"issue":"5","key":"2022111812330847700_CIT0004","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cgh.2007.01.015","article-title":"Trends in hospitalization rates for inflammatory bowel disease in the United States","volume":"5","author":"Bewtra","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"23","key":"2022111812330847700_CIT0005","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.3748\/wjg.v21.i23.7272","article-title":"Prevalence and predictors of hospitalization in Crohn\u2019s disease in a prospective population-based inception cohort from 2000\u20132012","volume":"21","author":"Golovics","year":"2015","journal-title":"World J Gastroenterol."},{"issue":"4","key":"2022111812330847700_CIT0006","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/gutjnl-2011-301397","article-title":"Hospitalisations and surgery in Crohn\u2019s disease","volume":"61","author":"Bernstein","year":"2012","journal-title":"Gut."},{"key":"2022111812330847700_CIT0007","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/ibd.20600","article-title":"How often do IBD patients require resection of their intestine?","volume":"14","author":"Hancock","year":"2008","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2022111812330847700_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis Foundation","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2022111812330847700_CIT0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ajg.2015.207","article-title":"Health insurance paid costs and drivers of costs for patients with Crohn\u2019s disease in the United States","volume":"111","author":"Park","year":"2016","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"2022111812330847700_CIT0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.cgh.2019.07.022","article-title":"Lifetime economic burden of Crohn\u2019s disease and ulcerative colitis by age at diagnosis","volume":"18","author":"Lichtenstein","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2022111812330847700_CIT0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MIB.0000000000000977","article-title":"The cost of Crohn\u2019s disease: varied health care expenditure patterns across distinct disease trajectories","volume":"23","author":"Rao","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2022111812330847700_CIT0012","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1185\/030079908X260790","article-title":"The costs of Crohn\u2019s disease in the United States and other Western countries: a systematic review","volume":"24","author":"Peng Yu","year":"2008","journal-title":"Curr Med Res Opin."},{"issue":"4","key":"2022111812330847700_CIT0013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"10","key":"2022111812330847700_CIT0014","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1365-2036.2001.01060.x","article-title":"Review article: the limitations of corticosteroid therapy in Crohn\u2019s disease","volume":"15","author":"Rutgeerts","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2022111812330847700_CIT0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0272-5231(05)70398-1","article-title":"Management of complications of glucocorticoid therapy","volume":"18","author":"Keenan","year":"1997","journal-title":"Clin Chest Med."},{"issue":"2","key":"2022111812330847700_CIT0016","first-page":"153","article-title":"Corticosteroid treatment in active Crohn\u2019s disease","volume":"61","author":"Belaiche","year":"1998","journal-title":"Acta Gastroenterol Belg."},{"year":"2002","author":"Food and Drug Administration","key":"2022111812330847700_CIT0017"},{"year":"2014","author":"Food and Drug Administration","key":"2022111812330847700_CIT0018"},{"issue":"1","key":"2022111812330847700_CIT0019","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology."},{"issue":"8","key":"2022111812330847700_CIT0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"issue":"12","key":"2022111812330847700_CIT0021","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"2","key":"2022111812330847700_CIT0022","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1053\/j.gastro.2021.06.040","article-title":"775d Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn\u2019s disease: the SEAVUE study","volume":"161","author":"Sands","year":"2021","journal-title":"Gastroenterology."},{"issue":"13","key":"2022111812330847700_CIT0023","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"year":"2020","author":"IBM Watson Health","key":"2022111812330847700_CIT0024"},{"issue":"9","key":"2022111812330847700_CIT0025","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","article-title":"Treatment patterns and sequencing in patients with inflammatory bowel disease","volume":"40","author":"Brady","year":"2018","journal-title":"Clin Ther."},{"issue":"12","key":"2022111812330847700_CIT0026","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cgh.2007.07.012","article-title":"The prevalence and geographic distribution of Crohn\u2019s disease and ulcerative colitis in the United States","volume":"5","author":"Kappelman","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"8","key":"2022111812330847700_CIT0027","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jclinepi.2014.02.019","article-title":"Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada","volume":"67","author":"Benchimol","year":"2014","journal-title":"J Clin Epidemiol."},{"issue":"9","key":"2022111812330847700_CIT0028","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/apt.13580","article-title":"Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis","volume":"43","author":"Singh","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"2022111812330847700_CIT0029","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/apt.12182","article-title":"Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease","volume":"37","author":"Long","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2022111812330847700_CIT0030","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease","volume":"24","author":"Dubinsky","year":"2018","journal-title":"Inflamm Bowel Dis."},{"author":"United States Bureau of Labor Statistics","key":"2022111812330847700_CIT0031"},{"key":"2022111812330847700_CIT0032","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"2022111812330847700_CIT0033","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/apt.15921","article-title":"Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn\u2019s disease","volume":"52","author":"Bohm","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2022111812330847700_CIT0034","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn\u2019s disease: results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology."},{"key":"2022111812330847700_CIT0035","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000001795","article-title":"Comparative effectiveness of biologics for endoscopic healing of the ileum and colon in Crohn\u2019s disease","author":"Narula","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2022111812330847700_CIT0036","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jgh.15107","article-title":"A propensity score weighted comparison of vedolizumab and adalimumab in Crohn\u2019s disease","volume":"36","author":"Macaluso","year":"2021","journal-title":"J Gastroenterol Hepatol."},{"issue":"9","key":"2022111812330847700_CIT0037","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cgh.2006.06.021","article-title":"Are perineal and luminal fistulas associated in Crohn\u2019s disease? A population-based study","volume":"4","author":"Tang","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2022111812330847700_CIT0038","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/gast.2002.32362","article-title":"The natural history of fistulizing Crohn\u2019s disease in Olmsted County, Minnesota","volume":"122","author":"Schwartz","year":"2002","journal-title":"Gastroenterology."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otac029\/45250696\/otac029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/4\/3\/otac029\/47118518\/otac029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/4\/3\/otac029\/47118518\/otac029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:34:29Z","timestamp":1668774869000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otac029\/6655822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otac029","relation":{},"ISSN":["2631-827X"],"issn-type":[{"type":"electronic","value":"2631-827X"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,7,1]]},"article-number":"otac029"}}